A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma

Inclusion Criteria:- Able to comprehend and sign an IRB approved Informed consent * Willingness and ability to comply with the FDA-mandated S.T.E.P.S.® program. * Male or female 18 years or older * Willing to use contraception * Pathologic diagnosis of renal cell carcinoma * Bi-dimensionally measurable disease * Evidence of disease progression prior to start of treatment * Failed prior immunotherapy or unwilling/unable to receive prior immunotherapy * Adequate hematologic data: ANC.1.5; platelets\>100x10\^9 * Adequate renal function: Creatinine clearance .50cc * Adequate liver function: Alkaline phos \<3XULN AST/ALT \<3XULN T.Bili \<1.5XULN * ECOG performance status 0-1 Exclusion Criteria:- Known brain metastases. * Peripheral neuropathy. * Pregnant and/ or lactating female. * Unable to take a baby aspirin.